2019
The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving
de Laat B, Goldberg A, Shi J, Tetrault JM, Nabulsi N, Zheng MQ, Najafzadeh S, Gao H, Kapinos M, Ropchan J, O'Malley SS, Huang Y, Morris ED, Krishnan-Sarin S. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving. Biological Psychiatry 2019, 86: 864-871. PMID: 31399255, DOI: 10.1016/j.biopsych.2019.05.021.Peer-Reviewed Original ResearchConceptsKappa-opioid receptorsAlcohol use disorderOpioid receptorsUse disordersNonselective opioid receptor antagonistModest clinical effectsEfficacy of naltrexoneOpioid receptor antagonistDSM-IV criteriaPositron emission tomographyAlcohol Urge QuestionnaireNaltrexone initiationNaltrexone therapyClinical effectsReceptor antagonistTherapeutic effectCingulate cortexDrinking paradigmHeavy drinkersBilateral insulaNaltrexoneAlcohol dependenceBrain regionsEmission tomographyPrefrontal cortex
2007
Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking
Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O’Malley S. Family History of Alcoholism Influences Naltrexone-Induced Reduction in Alcohol Drinking. Biological Psychiatry 2007, 62: 694-697. PMID: 17336941, DOI: 10.1016/j.biopsych.2006.11.018.Peer-Reviewed Original ResearchConceptsAlcohol drinkingFamily historyDrinking periodDose of naltrexoneSignificant clinical predictorsNaltrexone therapyClinical predictorsNaltrexone dosePriming doseMale drinkersNaltrexoneAlcohol-dependent participantsSecondary analysisDoseAlcoholic drinksDrinkingAlcoholismDrinkersDrinksDaysTotal numberParticipantsTherapy
2001
Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement
Carroll KM, Ball SA, Nich C, O'Connor PG, Eagan DA, Frankforter TL, Triffleman EG, Shi J, Rounsaville BJ. Targeting Behavioral Therapies to Enhance Naltrexone Treatment of Opioid Dependence: Efficacy of Contingency Management and Significant Other Involvement. JAMA Psychiatry 2001, 58: 755-761. PMID: 11483141, PMCID: PMC3651594, DOI: 10.1001/archpsyc.58.8.755.Peer-Reviewed Original ResearchConceptsDrug-free urine specimensNaltrexone treatmentFamily counseling sessionsContingency managementOpioid dependenceTreatment retentionUrine specimensBehavioral therapyOpioid-dependent individualsCounseling sessionsDrug use outcomesSubstance abuse outcomesNaltrexone complianceNaltrexone therapyOpioid useAvailable pharmacotherapiesMedication complianceSpecific pharmacotherapySignificant improvementTherapyUse outcomesAbuse outcomesPrincipal outcomePharmacotherapyTreatment
1998
A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic
O’Connor P, Oliveto A, Shi J, Triffleman E, Carroll K, Kosten T, Rounsaville B, Pakes J, Schottenfeld R. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. The American Journal Of Medicine 1998, 105: 100-105. PMID: 9727815, DOI: 10.1016/s0002-9343(98)00194-6.Peer-Reviewed Original ResearchConceptsPrimary care clinicsPrimary care settingBuprenorphine maintenanceCare clinicsDrug treatment programsHeroin dependenceOpioid useUrine toxicologyCare settingsTreatment programOpioid withdrawal symptomsOpioid-dependent patientsIllicit opioid useThrice weekly basisSecondary outcomesPrimary outcomeMaintenance treatmentWithdrawal symptomsMethadone clinicsPrimary careClinical trialsDrug treatmentEffective treatmentConsecutive weeksCocaine use
1997
Three methods of opioid detoxification in a primary care setting. A randomized trial.
O'Connor PG, Carroll KM, Shi JM, Schottenfeld RS, Kosten TR, Rounsaville BJ. Three methods of opioid detoxification in a primary care setting. A randomized trial. Annals Of Internal Medicine 1997, 127: 526-30. PMID: 9313020, DOI: 10.7326/0003-4819-127-7-199710010-00004.Peer-Reviewed Original ResearchConceptsPrimary care settingOpioid detoxificationCare settingsBuprenorphine groupWithdrawal symptomsDouble-blind clinical trialOpioid-dependent patientsHeroin-dependent patientsPrimary care clinicsWithdrawal symptom scoresSevere withdrawal symptomsDrug treatment programsSubstance abuse treatmentNaltrexone groupCare clinicsSymptom scoresPharmacologic protocolClinical trialsTreatment protocolClonidineTreatment retentionBuprenorphineNaltrexoneTreatment programAbuse treatment